What is polymyalgia rheumatica? Polymyalgia rheumatica causes muscle pain and stiffness in the neck, shoulder, and hip. The pain and stiffness usually occur in the morning or when you haven’t been moving for a while. It typically lasts longer than 30 minutes. For most people, the condition develops over time. But for some people it can start quickly – even overnight. In addition to stiffness, you may have a fever, weakness, and weight loss. Polymyalgia rheumatica usually goes away within one year, but it could last several years. People with polymyalgia rheumatica often have giant cell arteritis a disorder associated
Is your back hurting? You’re in good company. In any 3-month period, about 1 in 4 adults in the U.S. has at least one day of back pain, mostly in the lower back. The back is a complicated structure. Its center is the spine, which is made up of 33 bones called vertebrae, stacked in a column. The nerves of the spinal cord run in a tunnel through the middle of those bones. Spongy discs between the vertebrae act as cushions. Ligaments and tendons hold everything together. A lot of things can go wrong with your back. A strained muscle
What is Behçet’s disease? Behçet’s disease can affect different parts of your body. If you have the disease, you probably have sores in the mouth or on the genitals (sex organs). More serious symptoms can include swelling, heat, redness, and pain in the eyes and other parts of the body. The disease is named after the doctor who first described it, Dr. Hulusi Behçet.
What is back pain? Back pain is one of the most common medical problems in the United States. It might feel like a dull, constant ache or a sudden, sharp pain. Back pain can result from: An accident. A fall. Lifting something heavy. Changes that happen in the spine as you age. A disorder or medical condition. Treatment depends on the cause and symptoms of your pain. You can do things to improve your health and lower your chance of developing chronic (long-lasting) back pain.
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.